Trial Profile
Perhexiline improves myocardial energy deficiency and thereby diastolic function and exercise capacity in patients with cardiomyopathy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2010
Price :
$35
*
At a glance
- Drugs Perhexiline (Primary)
- Indications Cardiomyopathies
- Focus Pharmacodynamics
- 05 Nov 2010 New trial record.